United Therapeutics Corp (NASDAQ:UTHR)

CAPS Rating: 4 out of 5

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

Recs

1
Player Avatar cnbr1 (< 20) Submitted: 10/4/2006 9:44:01 AM : Underperform Start Price: $25.63 UTHR Score: -226.64

New PAH drugs will reduce UTHR's market; generic Flolan, Ambrisentan etc.

Featured Broker Partners


Advertisement